CN106146596A - A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound and extracting method, application - Google Patents
A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound and extracting method, application Download PDFInfo
- Publication number
- CN106146596A CN106146596A CN201610521687.2A CN201610521687A CN106146596A CN 106146596 A CN106146596 A CN 106146596A CN 201610521687 A CN201610521687 A CN 201610521687A CN 106146596 A CN106146596 A CN 106146596A
- Authority
- CN
- China
- Prior art keywords
- horneri
- turn
- sargassum
- compound
- spongocarpus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound and extracting method thereof, the Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound of the present invention has significant antidepressant effect, shown by the animal experiment in embodiment: Sitosterolum (β sitosterol) can significantly reduce mouse forced swimming test and the dead time of tail-suspention test small mouse, the little (TD of instant effect, toxic and side effects50> 2000mg/kg), can life-time service, demonstrate tool valuable as antidepressant pharmacological properties effect；Sitosterolum (β sitosterol) the raw materials of compound abundance of the present invention, cheap, extracting method is simple, can be made into the antidepressant drug of various dosage form.
Description
Technical field
The present invention relates to a kind of cupreol, especially relate to a kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound and extracting method thereof,
Application.
Background technology
Depression is also known as depressive disorder, low as main clinical characteristics with the most lasting mental state, is the master of mood disorders
Wanting type, clinical visible mental state is low unbecoming with its situation, and the downhearted of emotion can be felt oneself inferior from depressed to extremely grieved
Depression, the most pessimistic and worldweary, can there be suicidal attempt or behavior, even occur numb, some cases has obvious anxiety and motion
Property is intense, and the psychotic symptoms such as hallucination, vain hope occurs in severe patient.Depression can be to machines such as the digestion of people, immunity and nervous system
Impact can be produced, even cause damage, and this disease has high incidence, refractory more and the feature such as high relapse rate.
In clinical practice at present, existing multi-medicament is available for depression use, if Ah rice is for flat, clomipramine, chlorine shellfish
Amine, fluoxetine, paroxetine, Sertraline, citalopram etc., although these medicines can be used for varying degrees treatment or
Alleviate the misery of various depressive patients, but it exists side effect and feeling bad property, thus limit their life-time service.In order to
Eliminate or reduce toxic and side effects, improving therapeutic effect, need that there is new architectural feature and the novel compounds of the new mechanism of action
Thing.
Ocean is the field that on the earth, resource is the abundantest, and it is many that the special ecological environment of ocean creates marine organisms kind
Sample and particularity, the specificity making halobiontic a lot of characteristic and contained compound is that terrestrial organism does not has.Ocean
Biological medicament refers to the medicine extracted from marine animal and plant, and marine products animals and plants abundant in ocean not only provide for the mankind in a large number
Aquatic food, also provide many medicines for the mankind, and many marine drugs be evident in efficacy, cheap, effect uniqueness,
Therefore research marine drug tool is of great significance.Sargassum can produce enrich, the secondary metabolite of novel structure, war
Attract Marine Chemistry man and the dense research interest of medicine scholars always.Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.)Sargassu homedAs Brown algae one
Kind, have in China's Coastal Areas and be distributed widely, aboundresources, among the people can algae medication entirely.Find from natural plants, animal
The medicine that antidepressant activity is strong, toxic and side effects is extremely low has become domestic and international natural drug and has developed the focus of research.Particularly
Increasingly being paid attention to its chemical constitution with bioactive correlation research in recent years, this is to finding flavone from nature first
Lead compound and carry out structure of modification or modification, and the most significant to Development of New Drugs.
Summary of the invention
The goal of the invention of the present invention is to provide for a kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound.
Present invention also offers a kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound extracting method, processing step is simple, to equipment requirements
Low, low cost.
To achieve these goals, the present invention is by the following technical solutions:
A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound of the present invention, it is characterised in that described Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound chemical structure
Formula is shown below:
。
A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound extracting method, concretely comprises the following steps: take dry Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.), 95% after pulverizing
Ethanol soaks 2 ~ 3h, filters；Crude extract is obtained after extracting solution concentrating under reduced pressure desalination；Crude extract distilled water suspendible, uses stone successively
Oil ether, ethyl acetate, n-butanol extraction 4 times, obtain petroleum ether part extractum, take and wherein soak, with 300 ~ 400 mesh silica gel column chromatographies,
Petroleum ether-acetone gradient eluting repeatedly, Sephasex LH-20 purification, respectively obtain white solid matter (petroleum ether: acetone=
15:1), gained compound determines structure through IR, 1H-NMR, 13C-NMR, MS, is Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound.
The extracting method processing step of the present invention is simple, low for equipment requirements, low cost.
The application in medicine composition for treating depression of a kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound.
As preferably, described medicine composition for treating depression includes the Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound as active component, and
At least one pharmaceutical excipient.The pharmaceutical composition of the present invention refers in particular to be suitable for oral, non-bowel (vein or skin test) and intranasal
Those tablets of administration or sugar coated tablet, sublingual tablet, gelatine capsule, suppository, cream, ointment, skin gel,
Injectable formulation or drinkable suspension etc., specifically mentioned applicable oral, non-bowel (vein or skin test) and nasal administration
Those tablets or sugar coated tablet, sublingual tablet, gelatine capsule, suppository, cream, ointment, skin gel, injectable system
Agent or drinkable suspension etc..
As preferably, described pharmaceutical excipient is inert non-toxic excipient.
Therefore, there is advantages that
(1) providing a kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound, its abundant raw material source, cheap, preparation method is simple, can be made into each
Plant the antidepressant drug of dosage form or prescription common with other drug, make the antidepressant compound medicine of Mutiple Targets, instant effect, poison
Side effect little (TD50 > 2000mg/kg), can life-time service, demonstrate that tool valuable is made as antidepressant pharmacological properties
With；
(2) providing a kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound extracting method, processing step is simple, low for equipment requirements, low cost.
Accompanying drawing explanation
Fig. 1 is mouse forced swimming test test result.
Fig. 2 is Tail suspension test test result.
Fig. 3 is mice opening experiment test result.
Detailed description of the invention
Below by detailed description of the invention, the present invention will be further described.
In the present invention, if not refering in particular to, all percentage ratios are unit of weight, all devices and raw material and all can purchase from market
Or the industry conventional, method in following embodiment, if no special instructions, be this area conventional method.
Embodiment 1
A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound extracting method, concretely comprises the following steps: take dry Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.), after pulverizing 95% ethanol
Middle immersion 2.5h, filters；Crude extract is obtained after extracting solution concentrating under reduced pressure desalination；Crude extract distilled water suspendible, successively with petroleum ether,
Ethyl acetate, n-butanol extraction 4 times, obtain petroleum ether part extractum, take and wherein soak, with 380 mesh silica gel column chromatographies, petroleum ether-the third
Ketone gradient eluting repeatedly, Sephasex LH-20 purification, respectively obtain white solid matter (petroleum ether: acetone=15:1), gained
Compound is through IR, and 1H-NMR, 13C-NMR, MS determine structure, fusing point: 136.7-138.4 ° of C of Mp.; IR (KBr)
cm-1: 3397, 2932, 1644, 1470, 1341, 1050; 1H-NMR (CDCl3, 500 MHz): δ 0.78 (3H,
s, H-18), 1.02 (3H, d, H-21), 1. 08 (3H, s, H-19), 1.61 (3H, t, H-29), 2. 18
(1H, m, H-25), 3.60 (1H, m, H-3), 5.41 (1H, br d, J=5.12 Hz, H-6), 10.2 (1H,
s, -OH); 13C-NMR (CDCl3, 100 MHz): δ 141.21, 120.97, 72.06, 58.34, 56.76,
49.98, 47.13, 44.35, 41.98, 37.43, 37.21, 36.35, 34.09, 32.12, 32.01, 31.88,
30.46, 29.89, 28.02, 27.24, 27.28, 25.90, 23.71, 22.80, 21.35, 21.07, 19.89,
18.78, 12.77; ESI-HRMS calcd for C29H50O+ ([M+H]+): 415.3862; found: 415.3858。
The compound obtained is Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound, and its chemical structural formula is as follows:
。
Embodiment 2
A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound extracting method, concretely comprises the following steps: take dry Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.), after pulverizing 95% ethanol
Middle immersion 2h, filters；Crude extract is obtained after extracting solution concentrating under reduced pressure desalination；Crude extract distilled water suspendible, successively by petroleum ether, second
Acetoacetic ester, n-butanol extraction 4 times, obtain petroleum ether part extractum, take and wherein soak, with 300 mesh silica gel column chromatographies, petroleum ether-acetone
Gradient eluting repeatedly, Sephasex LH-20 purification, respectively obtain white solid matter (petroleum ether: acetone=15:1), gained
Compound is through IR, and 1H-NMR, 13C-NMR, MS determine structure, fusing point: 136.7-138.4 ° of C of Mp.; IR (KBr)
cm-1: 3397, 2932, 1644, 1470, 1341, 1050; 1H-NMR (CDCl3, 500 MHz): δ 0.78 (3H,
s, H-18), 1.02 (3H, d, H-21), 1. 08 (3H, s, H-19), 1.61 (3H, t, H-29), 2. 18
(1H, m, H-25), 3.60 (1H, m, H-3), 5.41 (1H, br d, J=5.12 Hz, H-6), 10.2 (1H,
s, -OH); 13C-NMR (CDCl3, 100 MHz): δ 141.21, 120.97, 72.06, 58.34, 56.76,
49.98, 47.13, 44.35, 41.98, 37.43, 37.21, 36.35, 34.09, 32.12, 32.01, 31.88,
30.46, 29.89, 28.02, 27.24, 27.28, 25.90, 23.71, 22.80, 21.35, 21.07, 19.89,
18.78, 12.77; ESI-HRMS calcd for C29H50O+ ([M+H]+): 415.3862; found: 415.3858。
The compound obtained is Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound, and its chemical structural formula is as follows:
。
Embodiment 3
A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound extracting method, concretely comprises the following steps: take dry Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.), after pulverizing 95% ethanol
Middle immersion 3h, filters；Crude extract is obtained after extracting solution concentrating under reduced pressure desalination；Crude extract distilled water suspendible, successively by petroleum ether, second
Acetoacetic ester, n-butanol extraction 4 times, obtain petroleum ether part extractum, take and wherein soak, with 400 mesh silica gel column chromatographies, petroleum ether-acetone
Gradient eluting repeatedly, Sephasex LH-20 purification, respectively obtain white solid matter (petroleum ether: acetone=15:1), gained
Compound is through IR, and 1H-NMR, 13C-NMR, MS determine structure, fusing point: 136.7-138.4 ° of C of Mp.; IR (KBr) cm-1: 3397, 2932, 1644, 1470, 1341, 1050; 1H-NMR (CDCl3, 500 MHz): δ 0.78 (3H,
s, H-18), 1.02 (3H, d, H-21), 1. 08 (3H, s, H-19), 1.61 (3H, t, H-29), 2. 18
(1H, m, H-25), 3.60 (1H, m, H-3), 5.41 (1H, br d, J=5.12 Hz, H-6), 10.2 (1H,
s, -OH); 13C-NMR (CDCl3, 100 MHz): δ 141.21, 120.97, 72.06, 58.34, 56.76,
49.98, 47.13, 44.35, 41.98, 37.43, 37.21, 36.35, 34.09, 32.12, 32.01, 31.88,
30.46, 29.89, 28.02, 27.24, 27.28, 25.90, 23.71, 22.80, 21.35, 21.07, 19.89,
18.78, 12.77; ESI-HRMS calcd for C29H50O+ ([M+H]+): 415.3862; found: 415.3858。
The compound obtained is Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound, and its chemical structural formula is as follows:
。
Below by concrete antidepressant pharmacological evaluation to evaluate antidepressant effect and the safety of the present invention:
Experiment material: healthy Balb/e mice, male, body weight 20 ± 2g, Zhejiang Medical academy of science animal experimental center provide,
Raise under the conditions of 25 DEG C.Keeping during experiment freely drinking water and taking food, feeding environment temperature is 23 ± 1 DEG C, humidity is 55 ±
5%, adaptability is tested after feeding 5-7 days, and every animal only uses once.
Positive control medicine: FLU(fluoxetine), it is purchased from Lilly company of the U.S., the medicine in following test 2.1,2.2
Using front fluoxetine normal saline to be configured to solution, cupreol (β-sitosterol) DMSO wiring solution-forming is used for abdominal cavity
Injection.All experiments were all carried out between 1 o'clock to 5 o'clock afternoon.
(1) mouse forced swimming test
Balb/e mice is randomly divided into 5 groups, often group 8, i.e. blank group, positive drug group (fluoxetine, 10 mg/
Kg), cupreol (β-sitosterol) high (30 mg/kg), in (20 mg/kg), low (10 mg/kg) dosage group.Each group is all
By 0.10 mL/20g body weight intraperitoneal injection, the DMSO of blank group injection equivalent.
After intraperitoneal injection 30 minutes, mice is put into XSC-mice constant temperature swimming instrument (depth of water 10cm, diameter 34cm
Bucket in, water temperature 23 ± 2 DEG C), in observing 6 minutes mice swimming situation, statistics mice after in 4 minutes swimming accumulation motionless time
Between (motionless i.e. mice stops struggling or mice is floating state, and mice extremity have mild action to keep head at the water surface).
Experimental result is as shown in Figure 1, it is seen that the antidepressant activity of this novel chalcone compound and positive drug control FLU
(fluoxetine) is similar, and the lowest (TD of neurotoxicity50> 2000mg/kg), safety is the highest.Cupreol (β-
Sitosterol) lumbar injection have compared with blank group under 30 mg/kg dosage significant difference (p<0.001), its
During middle lumbar injection 30 mg/kg dosage, its suppression dead time is similar to positive drug control group.
(2) mice rotation tail experiment
ZCR mice is randomly divided into 5 groups, often group 8, i.e. blank group, positive drug group (fluoxetine, 10 mg/kg),
Cupreol (β-sitosterol) high (30 mg/kg), in (20 mg/kg), low (10 mg/kg) dosage group.All press for each group
0.10 mL/20g body weight intraperitoneal injection, the DMSO of blank group injection equivalent.
After intraperitoneal injection 30 minutes, at the cm of mouse tail tip about 2, it is affixed on outstanding boot (30 cm × 30 with adhesive plaster
Cm × 25 cm) on support, make mice become reversal of the natural order of things state, its head, from bottom about 5cm, hangs 2 mices, centre dividing plate 1 time
Separate.The suspension time is 6 minutes, (motionless state i.e. mice stopping struggle of outstanding tail accumulation dead time in 4 minutes after statistics mice
Motionless or without any activity).
Experimental result is as shown in Figure 2, it is seen that this novel chalcone compound under 30 mg/kg dosage with blank group
Compare have significant difference (p<0.001), wherein the 30mg/kg group induction dead time is similar to positive drug, and this is described
Bright has antidepressant activity.
(3) mice opening experiment
Opening experiment is mainly for assessment of the autonomic activities behavior of laboratory animal, and in the present embodiment, opening experiment device is one
Opaque plastic box (80cm × 60cm × 30cm), is divided into the square of 48 10cm × 10cm sizes bottom plastic box
Grid, is placed in plastic box in quiet room, gives illumination with 60W bulb, and bulb is higher than plastic box center about 1m.
Take male mice 20, be randomly divided into 2 groups, often group 8, respectively blank group and medicine group.Test front 30
Min, is dissolved in cupreol (β-sitosterol) compound in DMSO solution, with the dosage lumbar injection 0.10 of 10 mg/kg
ML/20g, the DMSO solution of blank group lumbar injection same volume.Mice is placed in center grid at the bottom of plastic box, manually remembers
The mobile number of times (extremity both pass through grid) of record and setting number of times (standing with hind leg), record 3min.
Experimental result is as it is shown on figure 3, experimental result display mice autonomic activities number of times is the most obvious compared with matched group
Change, illustrate that this cupreol (β-sitosterol) will not change the autonomic activities of mice, eliminate cupreol (β-
Sitosterol) the antidepressant false positive of compound.
Embodiment described above is the one preferably scheme of the present invention, not makees the present invention any pro forma
Limit, on the premise of without departing from the technical scheme described in claim, also have other variant and remodeling.
Claims (5)
1. a Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound, it is characterised in that described Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound chemical structure formula is as follows
Shown in formula:
。
2. a Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound extracting method as claimed in claim, it is characterised in that concretely comprise the following steps:
Take dry Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.), in the ethanol of 95%, soak 2 ~ 3h after pulverizing, filter；Crude extract is obtained after extracting solution concentrating under reduced pressure desalination；Slightly
Extract distilled water suspendible, successively with petroleum ether, ethyl acetate, n-butanol extraction 4 times, obtains petroleum ether part extractum, takes wherein
Leaching, with 300 ~ 400 mesh silica gel column chromatographies, petroleum ether-acetone gradient eluting repeatedly, Sephasex LH-20 purification, respectively obtains
White solid matter (petroleum ether: acetone=15:1), gained compound determines knot through IR, 1H-NMR, 13C-NMR, MS
Structure, is Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound.
3. a Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound as claimed in claim 1 application in antidepressant drug.
The Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound the most according to claim 3 application in medicine composition for treating depression, its feature
Being, described medicine composition for treating depression includes the Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound as active component, and at least one is medicinal
Excipient.
The Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) cupreol compound the most according to claim 4 application in medicine composition for treating depression, its feature
Being, described pharmaceutical excipient is inert non-toxic excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610521687.2A CN106146596A (en) | 2016-07-05 | 2016-07-05 | A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound and extracting method, application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610521687.2A CN106146596A (en) | 2016-07-05 | 2016-07-05 | A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound and extracting method, application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106146596A true CN106146596A (en) | 2016-11-23 |
Family
ID=58061557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610521687.2A Pending CN106146596A (en) | 2016-07-05 | 2016-07-05 | A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound and extracting method, application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106146596A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018059241A1 (en) * | 2016-09-27 | 2018-04-05 | 广西久福生物科技有限公司 | Extract with detoxification pharmaceutical effect and preparation method therefor |
| CN112107606A (en) * | 2020-11-05 | 2020-12-22 | 陈乃宏 | Application of caulis sinomenii or extract thereof in preparation of antidepressant drugs |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977848A (en) * | 2005-12-08 | 2007-06-13 | 爱思开生物医药科技（上海）有限公司 | Use of steroidal compound and total steroidal extract for preparing anti-depression drug |
| CN102753181A (en) * | 2010-01-14 | 2012-10-24 | 优麦克里尼穆德公司 | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| CN103183715A (en) * | 2011-12-30 | 2013-07-03 | 中国科学院上海药物研究所 | Furostan saponin derivative and purpose thereof |
| CN103183719A (en) * | 2011-12-30 | 2013-07-03 | 中国科学院上海药物研究所 | Saponin derivative and application thereof |
| CN105777520A (en) * | 2014-12-23 | 2016-07-20 | 浙江海洋学院 | Novel chalcone compound Chalcone-1203, and composition, preparation method and application thereof |
| CN106146597A (en) * | 2016-07-05 | 2016-11-23 | 浙江海洋大学 | A kind of saringosterol compound and extracting method, application |
-
2016
- 2016-07-05 CN CN201610521687.2A patent/CN106146596A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977848A (en) * | 2005-12-08 | 2007-06-13 | 爱思开生物医药科技（上海）有限公司 | Use of steroidal compound and total steroidal extract for preparing anti-depression drug |
| CN102753181A (en) * | 2010-01-14 | 2012-10-24 | 优麦克里尼穆德公司 | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
| CN103183715A (en) * | 2011-12-30 | 2013-07-03 | 中国科学院上海药物研究所 | Furostan saponin derivative and purpose thereof |
| CN103183719A (en) * | 2011-12-30 | 2013-07-03 | 中国科学院上海药物研究所 | Saponin derivative and application thereof |
| CN105777520A (en) * | 2014-12-23 | 2016-07-20 | 浙江海洋学院 | Novel chalcone compound Chalcone-1203, and composition, preparation method and application thereof |
| CN106146597A (en) * | 2016-07-05 | 2016-11-23 | 浙江海洋大学 | A kind of saringosterol compound and extracting method, application |
Non-Patent Citations (1)
| Title |
|---|
| 袁清香等: "铜藻Sargassu Horneri 的化学成分研究", 《广东化工》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018059241A1 (en) * | 2016-09-27 | 2018-04-05 | 广西久福生物科技有限公司 | Extract with detoxification pharmaceutical effect and preparation method therefor |
| US10849934B2 (en) | 2016-09-27 | 2020-12-01 | Guangxi Jiufu Biotechnology Co., Ltd | Compound and preparation method thereof |
| US11116802B2 (en) | 2016-09-27 | 2021-09-14 | Guangxi Jiufu Biotechnology Co., Ltd | Extract effective in treating drug addiction and preparation method therefor |
| US11925665B2 (en) | 2016-09-27 | 2024-03-12 | Guangxi Jiufu Biotechnology Co., Ltd | Extract effective in treating drug addiction |
| CN112107606A (en) * | 2020-11-05 | 2020-12-22 | 陈乃宏 | Application of caulis sinomenii or extract thereof in preparation of antidepressant drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012343872B2 (en) | Vicenin 2 and analogues thereof for use as an antispasmodic and/or prokinetic agent | |
| CN104367765A (en) | Traditional Chinese medicinal composition for treating depression as well as preparation method and application thereof | |
| CN106146596A (en) | A kind of Sargassum phyllocystum Tseng et Lu,Sargassum horneri (Turn.) C. Ag. (Fucus horneri (Turn.)C.Ag.,Spongocarpus horneri Kutz.) Sitosterolum compound and extracting method, application | |
| CN106146597A (en) | A kind of saringosterol compound and extracting method, application | |
| CN102657686B (en) | Application of sea-buckthorn seed oil to preparation of medicament for preventing and/or treating depression | |
| Gidwani et al. | Analgesic, anti–inflammatory and anti–hemorrhoidal activity of aqueous extract of Lantana camara Linn | |
| CN105777520A (en) | Novel chalcone compound Chalcone-1203, and composition, preparation method and application thereof | |
| CN109942491A (en) | With the C of anti-inflammatory and analgesic effect in monkshood20Diterpene alkaloid and application thereof | |
| CN101172124B (en) | Novel uses of pennycress, pharmaceutical composition containing the pennycress and preparation method thereof | |
| Onasanwo et al. | Antidepressant and anxiolytic potentials of chebulinic acid in laboratory rodent | |
| CN106176748B (en) | Norisoboldine is preparing the purposes in anti-depression drug | |
| CN104497077B (en) | The extraction separation method of chromone ketoside compounds and the application in easing pain and diminishing inflammation medicine is prepared | |
| CN1686514A (en) | Chinese medicinal preparation for treating anxietas, depression and its production method | |
| CN106074643B (en) | Application of acanthopanax giraldii harms leaf and extract thereof in preparing anti-fatigue medicine or health food | |
| CN110279738A (en) | A kind of extracting method of antidepressant spermidine active component and the purposes of spermidine effective part extract | |
| CN101461803B (en) | Use of grape inner ester | |
| CN112279811A (en) | C20Diterpenoid alkaloids, their preparation and use for treating pain related diseases | |
| JP2021505692A (en) | New pharmaceutical use of persimmon leaf extract and its preparation | |
| CN104288142B (en) | The xylocarpus granatum element H and the like purposes in preparing anti-depression drug or food | |
| CN103980198A (en) | Alkaloid Casuarinine H and use thereof in preparation of medicines for treating neurodegenerative diseases | |
| CN106214689B (en) | Application of the rumicin -8-O- β-D- glucopyranoside in preparation antidepressant | |
| CN107007590A (en) | Purposes of the epimedium aglucone in prevention or treatment anti-parkinson drug is prepared | |
| EP2599488B1 (en) | Vicenin 2 and derivatives thereof for use as an antispasmodic and/or prokinetic agent | |
| CN105878258A (en) | Application of acteoside to preparation of antidepressant drugs | |
| Rauf et al. | The folkloric uses of medicinal plants in public health care |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161123 |